.Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AH06_Lumiracoxib.Lumiracoxib .Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M01A_AntiinflammatoryAndAntirheumaticProductsNonStero.M01AH06_Lumiracoxib.Lumiracoxib| name: | Lumiracoxib |
| ATC code: | M01AH06 | route: | oral |
| n-compartments | 1 |
Lumiracoxib is a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID) formerly used for relief of osteoarthritis and acute pain. It is no longer widely approved due to concerns over hepatotoxicity and has been withdrawn in most markets.
Pharmacokinetic parameters reported in healthy adult volunteers following single oral dose administration.
Scott, G, et al., & Ruff, DA (2004). Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clinical pharmacokinetics 43(7) 467–478. DOI:10.2165/00003088-200443070-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15139795
Scott, G, et al., & Rordorf, C (2004). Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. Clinical pharmacokinetics 43(5) 341–348. DOI:10.2165/00003088-200443050-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15080766
Vásquez-Bahena, DA, et al., & Trocóniz, IF (2010). Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. British journal of pharmacology 159(1) 176–187. DOI:10.1111/j.1476-5381.2009.00508.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19958362